Page last updated: 2024-10-24

positive regulation of monoatomic ion transmembrane transport

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate or extent of the directed movement of ions from one side of a membrane to the other. [GOC:mah]

Positive regulation of monoatomic ion transmembrane transport is a crucial biological process that involves the controlled movement of single-atom ions across cell membranes. This process is essential for maintaining cellular homeostasis, regulating membrane potential, and facilitating various physiological functions.

The regulation of monoatomic ion transport is a complex interplay of various mechanisms, including:

* **Protein Transporters:** Integral membrane proteins specifically designed to facilitate the movement of specific ions across the membrane. These transporters can be either passive, driven by the electrochemical gradient, or active, requiring energy to move ions against the gradient. Examples include sodium-potassium pumps, calcium channels, and chloride channels.

* **Channel Proteins:** These transmembrane proteins form pores that allow specific ions to pass through the membrane. They can be gated, opening and closing in response to specific stimuli such as voltage changes, ligand binding, or mechanical stress.

* **Signal Transduction Pathways:** External signals, such as hormones, neurotransmitters, or changes in environmental conditions, can activate intracellular signaling pathways that ultimately regulate the activity of ion transporters and channels. This regulation can involve phosphorylation, protein-protein interactions, or changes in gene expression.

* **Cellular Compartmentalization:** The localization of ion transporters and channels to specific cellular compartments contributes to the precise regulation of ion transport. For example, sodium-potassium pumps are concentrated in the plasma membrane, while calcium channels are found in the sarcoplasmic reticulum of muscle cells.

The positive regulation of monoatomic ion transmembrane transport involves mechanisms that enhance or increase the rate of ion transport across the membrane. This can be achieved by:

* **Increasing the number of active ion transporters or channels:** This can occur through increased gene expression, protein synthesis, or post-translational modifications.
* **Increasing the activity of existing transporters or channels:** This can involve changes in the affinity of the transporter for its substrate, modulation of channel gating, or alteration of the electrochemical gradient.
* **Removing inhibitory factors:** Some proteins or molecules can inhibit ion transport. Positive regulation can involve the removal or inactivation of these inhibitory factors.

The positive regulation of monoatomic ion transmembrane transport plays a vital role in various physiological processes, including:

* **Nerve Impulses:** The movement of sodium and potassium ions across the neuronal membrane is essential for generating and propagating nerve impulses.
* **Muscle Contraction:** Calcium ions are crucial for muscle contraction, and their release from the sarcoplasmic reticulum is regulated by ion channels.
* **Cellular Volume Regulation:** Cells maintain their volume through the controlled movement of ions and water across the membrane, which is regulated by ion transporters.
* **Hormone Secretion:** The secretion of hormones from endocrine cells often involves the regulated transport of ions across the membrane.

Dysregulation of monoatomic ion transmembrane transport can lead to various pathological conditions, such as:

* **Cardiac Arrhythmias:** Imbalances in ion transport can disrupt the electrical activity of the heart, leading to arrhythmias.
* **Muscle Weakness and Fatigue:** Disruptions in calcium transport can impair muscle function.
* **Neurological Disorders:** Altered ion transport in neurons can contribute to neurological conditions such as epilepsy and Alzheimer's disease.
* **Kidney Disease:** Imbalances in ion transport in the kidney can lead to electrolyte imbalances and kidney dysfunction.

In conclusion, positive regulation of monoatomic ion transmembrane transport is a fundamental process that is essential for maintaining cellular homeostasis and facilitating a wide range of physiological functions. The complex interplay of various regulatory mechanisms ensures the precise control of ion movement across cell membranes, ultimately contributing to overall organismal health.'
"

Proteins (2)

ProteinDefinitionTaxonomy
P2X purinoceptor 7A P2X purinoceptor 7 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99572]Homo sapiens (human)
Na(+)/H(+) exchange regulatory cofactor NHE-RF1A Na(+)/H(+) exchange regulatory cofactor NHE-RF1 that is encoded in the genome of human. [PRO:CNA, UniProtKB:O14745]Homo sapiens (human)

Compounds (20)

CompoundDefinitionClassesRoles
oxatomideoxatomide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug.

oxatomide: structure; an anti-allergic & an anti-asthmatic
benzimidazoles;
diarylmethane;
N-alkylpiperazine
anti-allergic agent;
anti-inflammatory agent;
geroprotector;
H1-receptor antagonist;
serotonergic antagonist
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
arenesulfonic acid;
azobenzenes;
methylpyridines;
monohydroxypyridine;
organic phosphate;
pyridinecarbaldehyde
purinergic receptor P2X antagonist
suraminsuramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.

Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
naphthalenesulfonic acid;
phenylureas;
secondary carboxamide
angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
alpha,beta-methyleneadenosine 5'-triphosphatealpha,beta-methyleneadenosine 5'-triphosphate: do not confuse with beta,gamma-methylene ATP; RN given refers to parent cpdnucleoside triphosphate analogue
sb 203580imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
8-azidoadenosine 5'-triphosphate
6-thioinosine-5'-triphosphateorganic molecule
fh535FH535: inhibits Wnt signalingsulfonamide
mrs2159MRS2159: an antagonist of both P2X1 and P2X7 receptors
imd 0354N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first sourcebenzamides
kn 62KN 62: inhibitor of Ca/calmodulin-dependent protein kinase IIpiperazines
az 11645373AZ 11645373: InChIKey: VQEHBLGYANQWEA-UHFFFAOYSA-N
az10606120AZ10606120: a P2X7 receptor antagonist
ce 224,535CE 224,535: structure in first source
a-438079
af 3535-(5-iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2,4-diamine: a P2X3 and P2X2/3 receptor antagonist; structure in first source
gsk1482160
a-839977A-839977: a selective P2X7 receptor antagonist, analgesic; structure in first source
jnj-47965567JNJ-47965567: a P2X7 purinergic receptor antagonist; structure in first source
mk-8742elbasvir : A complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.

elbasvir: inhibits NS5A protein of hepatitis C virus
carbamate ester;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heterotetracyclic compound;
ring assembly
antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor;
hepatoprotective agent